Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Duchenne Muscular Dystrophy: Clinical Characteristics, Molecular Mechanisms and Management

View through CrossRef
The dystrophinopathies encompass a range of X-linked muscle disorders varying from mild to severe, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated dilated cardiomyopathy (DCM). DMD typically manifests in early childhood and progresses rapidly, with affected children becoming wheelchair-dependent by the age of 12. Increased serum CK levels are detected in almost all DMD patients. Pathogenic variants in the DMD gene affect dystrophin expression, leading to DMD. More than four thousand pathogenic variants have been identified in the DMD gene. deletions of one or more exons are the most common variants in the DMD gene and are found in 60%-70% of patients. With current genetic methods, it is possible to elucidate the molecular etiology in approximately 95% of patients. Penetrance of DMD is complete in males. The penetrance varies in heterozygous carrier females and may depend, partly, X-chromosome inactivation (XCI) patterns. Since DMD has X-linked inheritance pattern, carrier screening should always be considered for mothers of boys with DMD. There are two important points to remember in genetic counseling for DMD. One is that 33% of DMD cases are sporadic (de novo), and the other is that the probability of germline mosaicism for DMD is 15%-20%. Sarcoglycanopathies, Emery-Dreifuss muscular dystrophy, and Barth syndrome are diseases that are included in the differential diagnosis of DMD. Since multiple systems can be affected in DMD patients, management ideally should be provided within a multidisciplinary care setting. Although corticosteroids have been shown to increase muscle strength in DMD patients and are frequently used, they are not a curative treatment. In recent years, antisense oligonucleotides and nonsense suppression therapies have emerged as variant-specific treatments. Also, several new and promising therapies have entered clinical trials or are on the horizon. In this chapter, in addition to this summary about DMD, more comprehensive information is provided.
Title: Duchenne Muscular Dystrophy: Clinical Characteristics, Molecular Mechanisms and Management
Description:
The dystrophinopathies encompass a range of X-linked muscle disorders varying from mild to severe, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated dilated cardiomyopathy (DCM).
DMD typically manifests in early childhood and progresses rapidly, with affected children becoming wheelchair-dependent by the age of 12.
Increased serum CK levels are detected in almost all DMD patients.
Pathogenic variants in the DMD gene affect dystrophin expression, leading to DMD.
More than four thousand pathogenic variants have been identified in the DMD gene.
deletions of one or more exons are the most common variants in the DMD gene and are found in 60%-70% of patients.
With current genetic methods, it is possible to elucidate the molecular etiology in approximately 95% of patients.
Penetrance of DMD is complete in males.
The penetrance varies in heterozygous carrier females and may depend, partly, X-chromosome inactivation (XCI) patterns.
Since DMD has X-linked inheritance pattern, carrier screening should always be considered for mothers of boys with DMD.
There are two important points to remember in genetic counseling for DMD.
One is that 33% of DMD cases are sporadic (de novo), and the other is that the probability of germline mosaicism for DMD is 15%-20%.
Sarcoglycanopathies, Emery-Dreifuss muscular dystrophy, and Barth syndrome are diseases that are included in the differential diagnosis of DMD.
Since multiple systems can be affected in DMD patients, management ideally should be provided within a multidisciplinary care setting.
Although corticosteroids have been shown to increase muscle strength in DMD patients and are frequently used, they are not a curative treatment.
In recent years, antisense oligonucleotides and nonsense suppression therapies have emerged as variant-specific treatments.
Also, several new and promising therapies have entered clinical trials or are on the horizon.
In this chapter, in addition to this summary about DMD, more comprehensive information is provided.

Related Results

Role of Growth Factors and Apoptosis Proteins in Cognitive Disorder Development in Patients with Duchenne Muscular Dystrophy
Role of Growth Factors and Apoptosis Proteins in Cognitive Disorder Development in Patients with Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease; it occurs due to a mutation in the dystrophin protein gene; as a result, the protein is not synthesized an...
Duchenne De Boulogne: A Pioneer in Neurology and Medical Photography
Duchenne De Boulogne: A Pioneer in Neurology and Medical Photography
ABSTRACT:Guillaume-Benjamin-Amand Duchenne was born 200 years ago in Boulogne-sur-Mer (Pas-de-Calais, France). He studied medicine in Paris and became a physician in 1831. He pract...
Advanced Physiotherapy Intervention for Muscular Dystrophy
Advanced Physiotherapy Intervention for Muscular Dystrophy
Muscular dystrophies are rare neuromuscular conditions which are genetically and clinically diverse that cause gradual, progressive weakness and breakdown of skeletal muscles over ...
INFLUÊNCIA DO EXERCÍCIO FÍSICO NA DISTROFIA MUSCULAR DE DUCHENNE: UMA REVISÃO SISTEMÁTICA
INFLUÊNCIA DO EXERCÍCIO FÍSICO NA DISTROFIA MUSCULAR DE DUCHENNE: UMA REVISÃO SISTEMÁTICA
Objetivo: Avaliar a influência da prática do exercício físico na distrofia muscular de duchenne. Método: Revisão Sistemática sem metanálise, de todos os artigos publicados nas base...
Duchene’s muscular dystrophy: a clinical case
Duchene’s muscular dystrophy: a clinical case
Background. Muscular dystrophy is a heterogeneous group of genetic disorders characterized by progressive loss of skeletal muscles. Duchene's muscular dystrophy (MDD) is one of the...
Clinico-pathological Diagnosis of Facioscapulohumeral Dystrophy in a 22-year-old Male
Clinico-pathological Diagnosis of Facioscapulohumeral Dystrophy in a 22-year-old Male
Background: Facioscapulohumeral dystrophy (FSHD) is a rare hereditary disease with a prevalence of 2.03–6.8 per 100,000 individuals. FSHD is the third most common type of muscular ...
Respiratory care in muscular dystrophy
Respiratory care in muscular dystrophy
Abstract Respiratory problems are a major cause of morbidity and mortality in the muscular dystrophies. Indeed, in Duchenne muscular dystrophy (DMD) respiratory comp...

Back to Top